Prosecution Insights
Last updated: November 17, 2026
Application No. 18/256,329

REACTIVE MICROPARTICLES AND THEIR USE TO PREPARE FUNCTIONAL HYDROGEL PARTICLES

Non-Final OA §102§103§112
Filed
Jun 07, 2023
Priority
Dec 07, 2020 — provisional 63/122,322 +1 more
Examiner
DAVIS, BRIAN J
Art Unit
1614
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Allarta Life Science Inc.
OA Round
1 (Non-Final)
85%
Grant Probability
Favorable
1-2
OA Rounds
81%
With Interview

Examiner Intelligence

Grants 85% — above average
85%
Career Allowance Rate
1353 granted / 1595 resolved
+24.8% vs TC avg
Minimal -4% lift
Without
With
+-3.9%
Interview Lift
resolved cases with interview
Typical timeline
Avg Prosecution
43 currently pending
Career history
1643
Total Applications
across all art units

Office Action

§102 §103 §112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Election/Restriction Inventor’s election, without traverse (no arguments), of the microparticle MED-55/5/5 of Table 1 (specification page 59) where MED-X/Y/Z is defined as follows: X represents the volume percentage of MEK in the MEK/Heptane co-solvent mixture, and Y and Z represents the mole percentages of the two permanent crosslinkers, EGDMA and DEGDMA in the total monomer pool with the remaining amount representing MeAn. The election/restriction was made merely in order to facilitate the reasonably complete and thorough search of the claimed subject matter to which inventor is entitled and is hereby made FINAL. Information Disclosure Statement The lined-through reference is incomplete. Note that each publication listed in an information disclosure statement must be identified by publisher, author (if any), title, relevant pages, date, and place of publication. (See Rule 1.98(b)(5).) Note also, if applicable, MPEP 707.05(e)(IV) for examples of proper citation format for electronic documents. Claim Objections Claim 5 is objected to because of the following informalities: in the last line of the claim, the term “…combinationsof…should, of course, properly be: combinations of. Appropriate correction is required. Inventor’s assistance is respectfully requested in correcting any other minor spelling and/or grammatical errors which may be present in the claim set. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 1-3 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. The terms “temporary crosslinker” and “permanent crosslinker” are relative terms which render the claims indefinite. The terms are not defined by the claims, the specification does not provide a standard for ascertaining the requisite degree, and one of ordinary skill in the art would not be reasonably apprised of the scope of the invention. What is, or is not, a temporary crosslinker or a permanent crosslinker would seem to be the most subjective of determinations and depend almost - if not, in fact, entirely - on a particular set of reaction conditions. Clarification is very much in order. Claims 7 and 14 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. The term “temporary crosslinker” is a relative term which renders the claims indefinite. The term is not defined by the claims, the specification does not provide a standard for ascertaining the requisite degree, and one of ordinary skill in the art would not be reasonably apprised of the scope of the invention. What is, or is not, a temporary crosslinker would seem to be the most subjective of determinations and depend almost - if not, in fact, entirely - on a particular set of reaction conditions. Clarification is very much in order. Claims 8, 10 and 17 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. The term “permanent crosslinker” is a relative term which render the claims indefinite. The term is not defined by the claims, the specification does not provide a standard for ascertaining the requisite degree, and one of ordinary skill in the art would not be reasonably apprised of the scope of the invention. What is, or is not, a permanent crosslinker would seem to be the most subjective of determinations and depend almost - if not, in fact, entirely - on a particular set of reaction conditions. Clarification is very much in order. Claim 13 is rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. The limitation “…less than 1% surfactant and/or stabilizer…” is unclear. Is this a mole %? Weight %? Clarification is in order. Claim 14 is rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. It is unclear when exactly the step of functionalizing the monomers of the temporary crosslinkers takes place. That is, before, during, or after the combining and precipitation steps of claim 1 (the claim from which claim 14 immediately depends)? Clarification is in order. Claims 4, 5, 6, 9, 12, 15, 16 and 28-31 are also rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. The claims all depend, or ultimately depend, upon an indefinite base claim yet do not completely relieve the indefiniteness. Dependent claims 4, 5, 6, 9, 12, 15, 16 and 28-31 are also, therefore, indefinite. Markush Search All claims have been examined with respect to formal matters. The elected species has been searched and is deemed free of the prior art. The search was therefore expanded, as called for under Markush examination practice, to include a single additional species. That species is defined when: the microparticle comprises methacrylic anhydride as the temporary crosslinker and ethyleneglycol dimethacrylate (EGDMA) as the permanent crosslinker. All claimed but as yet unexamined subject matter is hereby withdrawn from consideration, for purposes of this Office Action, as being drawn to non-elected subject matter. This subject matter will be rejoined as appropriate as the Markush examination progresses. Claim Rejections - 35 USC § 102 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claims 1, 5-9 and 14, in so far as they read on the species defined above, are rejected under 35 U.S.C. 102(a)(1) as being clearly anticipated by GB 1,431,940, cited in the IDS. The reference teaches a method of producing a microparticle comprising methacrylic anhydride (i.e. a temporary crosslinker) and ethyleneglycol dimethacrylate (i.e. a permanent crosslinker) by precipitation polymerization in a solvent comprising n-heptane (page 9, Example 1). The microparticles so formed have a particle size in the unswollen state of 0.1-1.0 mm (100-1000 µm) (page 7, line 63). The microparticles so formed are then further functionalized with biologically active substances (page 12, Example 10). Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claims 2, 3 and 10, in so far as they read on the species defined above, are rejected under 35 U.S.C. 103 as being unpatentable over GB 1,431,940, cited in the IDS. Inventor teaches a method of producing microparticles by precipitation polymerization comprising combing at least one temporary crosslinker and at least one permanent crosslinker in a suitable organic solvent thereby forming the microparticles, wherein a total monomer loading is calculated and specified (claim 2). Inventor teaches a method of producing microparticles by precipitation polymerization comprising combing at least one temporary crosslinker and at least one permanent crosslinker in a suitable organic solvent thereby forming the microparticles, wherein a total crosslinker loading, and a ratio of temporary to permanent crosslinker, is specified (claim 3). Inventor teaches a method of producing microparticles by precipitation polymerization comprising combing at least one temporary crosslinker and at least one permanent crosslinker in a suitable organic solvent thereby forming the microparticles, wherein a permanent crosslinker loading is specified (claim 10). GB 1,431,940 has been outlined above (102 rejection). Inventor distinguishes over the cited art in that specific monomer loading parameters are explicitly specified. However, precipitation polymerization is an old and well-known technique in the chemical arts, just as the starting prior art monomers are old and well-known polymerization monomers, and one of ordinary skill in the art, before the effective filing date of the instant invention and with a reasonable expectation of success, would have found it obvious to tune or optimize the monomer loading parameters in order to tune or optimize the microparticles so produced. One of ordinary skill would have immediately recognized that tuning or optimizing results-effective variables, such as monomer loadings, are a means of tuning or optimizing the characteristics of the microparticles so produced so that the microparticles might be tailored to a particular application. This is simply part and parcel of precipitation polymerization design and subsequent microparticle synthesis. Allowable Subject Matter The elected species being free of the prior art, any claim, or portion of a claim, drawn exclusively to this species constitutes allowable subject matter. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to BRIAN J DAVIS whose telephone number is (571)272-0638. The examiner can normally be reached M-F 8:30-5:00 PM EDT. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Ali Soroush, can be reached at 571-272-9925. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /BRIAN J DAVIS/Primary Examiner, Art Unit 1614 10/24/2026
Read full office action

Prosecution Timeline

Jun 07, 2023
Application Filed
May 11, 2026
Response after Non-Final Action
Jun 26, 2026
Interview Requested
Jul 07, 2026
Examiner Interview Summary
Jul 07, 2026
Applicant Interview (Telephonic)
Aug 07, 2026
Response Filed
Oct 28, 2026
Non-Final Rejection mailed — §102, §103, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12788819
Formulated and/or co-formulated liposome compositions containg TGFb antagonist prodrugs useful in the treatment of cancer and methods thereof
3y 4m to grant Granted Nov 10, 2026
Patent 12788763
SULFONAMIDE OR SULFINAMIDE COMPOUND HAVING EFFECT OF INDUCING BRD4 PROTEIN DEGRADATION AND PHARMACEUTICAL USE THEREOF
2y 3m to grant Granted Nov 10, 2026
Patent 12788702
HAIR SHAMPOO WITH NATURAL OIL
2y 1m to grant Granted Nov 10, 2026
Patent 12778906
PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING MUSCULAR WEAKNESS-RELATED DISEASES COMPRISING ALVERINE, 4-HYDROXY ALVERINE, DERIVATIVE THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF
4y 0m to grant Granted Nov 03, 2026
Patent 12758498
A TOPICAL GEL FORMULATION FOR SKIN AND MOUTH DISORDERS AND A PROCESS OF PREPARATION THEREOF
2y 3m to grant Granted Oct 13, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
85%
Grant Probability
81%
With Interview (-3.9%)
Low
PTA Risk
Based on 1595 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month